We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

84 hedge funds and large institutions have $207M invested in Adamas Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

10% less funds holding

Funds holding: 9384 (-9)

27% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 26

34% less capital invested

Capital invested by funds: $316M → $207M (-$108M)

Holders
84
Holders Change
-9
Holders Change %
-9.68%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
19
Increased
38
Reduced
15
Closed
26
Calls
$37K
Puts
Net Calls
+$37K
Net Calls Change
-$690K
Name Holding Trade Value Shares
Change
Change in
Stake
AQR Capital Management
101
AQR Capital Management
Connecticut
-$282K -9,964 Closed
Susquehanna International Group
102
Susquehanna International Group
Pennsylvania
-$236K -8,322 Closed
GCP
103
GSA Capital Partners
United Kingdom
-$215K -7,600 Closed
Two Sigma Advisers
104
Two Sigma Advisers
New York
-$201K -7,100 Closed
Bank of America
105
Bank of America
North Carolina
-$94K -3,319 Closed
Group One Trading
106
Group One Trading
Illinois
-$66K -2,330 Closed
BNP Paribas Financial Markets
107
BNP Paribas Financial Markets
France
-$57.9K -2,046 Closed
UBS Group
108
UBS Group
Switzerland
-$54K -1,891 Closed
Creative Planning
109
Creative Planning
Kansas
-$387 -23 -47%

ADMS Hedge Fund Activity: Q1 2016 in Review

84 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2016, worth a combined $207M — down 34% from $316M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ADMS and 19 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 38 added.

The largest buyer was Great Point Partners, adding an estimated $11.3M. The largest seller was Millennium Management, cutting an estimated $6.05M.

  • 84 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2016, down from 93 in Q4 2015.
  • Funds reported $207M of Adamas Pharmaceuticals stock for Q1 2016, down 34% quarter-over-quarter.
  • 19 funds opened new Adamas Pharmaceuticals positions in Q1 2016 and 26 closed out, a net change of -7 holders.
  • The largest Adamas Pharmaceuticals buyer in Q1 2016 was Great Point Partners, an estimated $11.3M added.
  • The largest Adamas Pharmaceuticals seller in Q1 2016 was Millennium Management, an estimated $6.05M sold.

Based on aggregated 13F filings for Q1 2016.